Thelansis

 Alopecia areata is an autoimmune disorder that leads to temporary hair loss without scarring, with hair follicles remaining intact. Hair loss varies from distinct patches to widespread loss, affecting all hair-bearing areas, with scalp patchy alopecia being the most common. It impacts nearly 2% of the general population at some point. Most individuals with alopecia areata experience isolated circular hair loss patches on the scalp, eyebrows, eyelashes, or body, while some have extensive or total hair loss. Diagnosis is often based on hair loss patterns and history; occasionally, a biopsy may be required for confirmation. The typical age of diagnosis is 33, with males often diagnosed in childhood and females in adolescence—about 60% experience initial hair loss before age 20. Traditional treatments involve steroids administered via injection or topical application to affected areas. Steroids suppress the immune cells attacking hair follicles, promoting hair regrowth. ·  ...

 Alopecia areata is a common autoimmune disorder that often results in unpredictable hair loss. It is an autoimmune disorder in which a misguided immune system damages hair follicles. ·        Prevalence in the general population is 0.1-0.2%. The lifetime risk of developing alopecia areata is estimated to be 1.7%; Alopecia areata is responsible for 0.7-3% of patients seen by dermatologists. ·        The median age at diagnosis is 33. Male patients may be more likely to be diagnosed in childhood, while females are more likely to present in adolescence. About 60% of people with alopecia areata experience the first hair loss episode before age 20. Thelansis’s “Alopecia Areata Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, p...